Pioglitazone
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Pioglitazone: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Pioglitazone is a thiazolidinedione (TZD)-class insulin sensitizer, traditionally used to improve glycemic control in type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare skeletal dysplasia, but this prediction is currently supported by 0 clinical trials and 0 publications, and the model's own rationale notes no known biological link between the drug's mechanism and this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (based on known drug class; not explicitly recorded in this evidence pack) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| Germany Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known information, pioglitazone is a thiazolidinedione (PPAR-γ agonist) that improves peripheral insulin sensitivity and has demonstrated efficacy in type 2 diabetes mellitus, including protective effects on β-cell function and cardiovascular risk markers.
Opsismodysplasia, however, is a skeletal developmental disorder associated with INT complex genes (INTS8/RSPRY1), a pathway with no established interaction with PPAR-γ signaling. The evidence pack's own repurposing rationale explicitly states that this TxGNN score reflects a graph-embedding association rather than a biologically grounded hypothesis, and that no mechanistic rationale can currently be articulated for this drug-disease pair.
Given the absence of any mechanistic overlap, clinical trial data, or supporting literature, this prediction should be treated as a pure model output requiring independent biological validation before any further evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Germany Market Information
Pioglitazone currently has no marketing authorizations on record in Germany (market status: Not Marketed, 0 total licenses).
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications are flagged as a Blocking data gap — required before any S1 safety review can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (opsismodysplasia) is supported only by a model similarity score (L5, Evidence Level), with zero clinical trials, zero literature, and no plausible mechanistic link between PPAR-γ agonism and this INT-complex-related skeletal disorder — a limitation the model's own rationale explicitly acknowledges.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for pioglitazone (currently a data gap)
- TFDA/BfArM label warnings and contraindications (Blocking gap — required before S1 safety evaluation)
- Independent mechanistic or preclinical evidence connecting PPAR-γ signaling to INT-complex-associated skeletal pathology
- If pursuing repurposing research, consider prioritizing the pack's lower-ranked lipodystrophy-related predictions (ranks 5–8) instead, as these have a documented PPAR-γ/adipogenesis mechanistic rationale, even though they too currently lack clinical or trial evidence and remain at the "Research Question" stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.